LifeSciVC

APRIL 2, 2024

We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. And the experience of those around you, including Board members and internal investors.

Science 69

Science Small Molecule International Clinical Development 69

The Pharma Data

DECEMBER 12, 2020

AstraZeneca , with Alexion ‘s R&D team, will work to build on Alexion ‘s pipeline of 11 molecules across more than 20 clinical-development programmes across the spectrum of indications, in rare diseases and beyond. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

JUNE 2, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. ” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. pneumoniae invasive disease and pneumonia in adults 50 years and above.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. pneumoniae invasive disease and pneumonia in adults 50 years and above.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

Drug Target Review

MARCH 20, 2025

The landscape of anticoagulation therapy could be on the brink of a major transformation. GI bleeding can lead to patients temporarily or permanently discontinuing their anticoagulation therapy, significantly increasing their stroke risk. “When someone has a GI bleed, they often stop taking their anticoagulant.

Therapies 52

Therapies Trials Clinical Development FDA 52